The Standard Zanu PF’s provincial leaders in Manicaland survived an ouster plot as factional wars in the ruling party that were ignited by the influence of wealthy businessmen around President ...

Targeting Ore Reserves, PFS and ML application by the end of 2026HIGHLIGHTSMay 2025 Optimised Scoping Study (OSS) ...

Q4 2025 earnings call: ivonescimab Phase III updates, FDA PDUFA timeline, interim PFS in Q2 2026, cash position—read now.

Learn why Water for Injection (WFI) is a strategic utility in sterile drug manufacturing and how outsourcing WFI production ...

Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral therapy, in combination with everolimus, for the treatment of adult patients ...

Extensive metallurgical testwork and technical/infrastructure studies ongoing towards the planned publication of a PFS towards the end of 2026.

Including PFS as an interim primary endpoint provides a potential pathway to shorten the duration of VERSATILE-003 and accelerate the timeline to regulatory submission, as well as making the trial ...

US FDA accepts Roche’s NDA for giredestrant in ESR1-mutated, ER-positive advanced breast cancer: Basel Saturday, February 21, 2026, 11:00 Hrs [IST] Roche announced that the Unit ...

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune ...

Princeton, New Jersey Thursday, February 19, 2026, 11:00 Hrs [IST] ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...